Sevasemten
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Sevasemten
- Molecular weight
- 381.29
- Structure (SMILES)
- O=c1ccc(-c2cnc(OCC(F)(F)F)nc2)nn1Cc1cncc(F)c1
- edg 005506
- edg 5506
- edg 5506 tablet
- EDG-005506
- Edg-5506
- EDG-5506
- EDG-5506 Tablet
- sevasemten
- Sevasemten
- sevasemten [INN]
- SEVASEMTEN [USAN]
- Sevasemten [WHO-DD]
- sevasemten 10 mg
- Sevasemten 10 mg
- sevasemten 12 5 mg
- Sevasemten 12.5 mg
- sevasemten 5 mg
- Sevasemten 5 mg
- sevasemten inn
- sevasemten usan
- sevasemten who dd
- CAS registry numbers
- 2417395-15-2
- ChEMBL ID
- CHEMBL5314486
- InChIKey
- XFPJKQRXBAFXNK-UHFFFAOYSA-N
- PubChem compound IDs
- 149205919
- FDA ingredient codes (UNII)
- JT5OYR0WUK
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- sevasemten
- Type
- Synthetic organic
- Drug name stem
- -semten
- Condition
- Muscular Dystrophy, Duchenne
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0010311
- Subject identifier
- D020388
- Condition
- Muscular Dystrophy, Duchenne
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0010679
- Subject identifier
- D020388
- Condition
- Muscular Dystrophies
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0020121
- Subject identifier
- D009136
- Condition identifier
- MONDO_0010311
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0010679
- Condition identifier
- MONDO_0010679
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0020121
- Condition identifier
- MONDO_0020121
- Highest recorded phase
- 1
- NCT04585464
- NCT05160415
- NCT06066580
- NCT05492734
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 0
- Polar surface area
- 82.79
- Calculated partition coefficient (ALogP)
- 2.22
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 27
- Molecular formula
- C16H11F4N5O2
- Monoisotopic mass
- 381.08488726
- Natural product
- No
- Recorded assays
- 2
- Active assays
- 1
Active assay types
- Confirmatory
Related records
Trials (9)
- A Study of EDG-5506 in Adult Males With Becker Muscular Dystrophy
- A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
- A Study to Assess Safety, Tolerability, and PK of EDG-5506 in Healthy Volunteers and Becker Muscular Dystrophy Adults
- A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling
- A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
- Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers
- Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
- Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
- Phase 2 Study of EDG-5506 in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy
In development for (3)
- Becker muscular dystrophy Phase 2
- Duchenne muscular dystrophy Phase 2
- Muscular dystrophy Phase 1